2001 Fiscal Year Final Research Report Summary
A new type of neutron capture therapy against malignant tumors using medical nuclear reactor
| Project/Area Number |
11794021
|
|---|
| Research Category |
Grant-in-Aid for University and Society Collaboration
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
MATSUMURA Akira Institute of Clinical Medicine, Associate Professor, 臨床医学系, 助教授 (90241819)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHTSUKA Fujio Institute of Clinical Medicine, Professor, 臨床医学系, 教授 (10092157)
TAKANO Shingo Institute of Clinical Medicine, Assisstant Professor, 臨床医学系, 講師 (50292553)
NOSE Tadao Institute of Clinical Medicine, Professor, 臨床医学系, 教授 (10009699)
OHARA Kiyoshi Institute of Clinical Medicine, Associate Professor, 臨床医学系, 助教授 (10034125)
FUJISAWA Hiroshi Institute of Clinical Medicine, Assisstant Professor, 臨床医学系, 講師 (20231566)
|
|---|
| Project Period (FY) |
1999 – 2001
|
| Keywords | neutron capture therapy / charged particle therapy / alpha particle / malignant glioma / glioblastoma / boron / radiation therapy / intraoperative radiation therapy |
|---|
| Research Abstract |
[Basic Physics Study] Before using epi-thermal neutron to the patients, basic studies for neutron beam characterization have been performed. We used water phantom, cultured cells for measurement. The RBE of the each beam component has been calculated, which can be applied to the clinical dose evaluation. Besides, the treamtne planning system (so called JCDS system) has been also developed for JRR-4 boron neutron capture therapy (BNCT) project.
[Basic Oncology Study] To improve the boron delivery to the tumor cells, we have developed a new boronated porphyrin and have examined using in vitro cultured glioma cells and have shown that this compound effectively accumulate in the tumor cells and show cytotoxic effect after neutron irradiation. We have also analyzed the boron uptake in two boronated compounds currently used in clinical trial by means of the cell cycle dependency. Both compound showed different behavior and based on this result we may use two compounds simultanesouly for clinical trial since they cover different cell population in the cell cycle.
[Clinical Study] Since October 1999, a new clinical phase I/II trial using mixed thermal-epithermal beam with open craniotomy has been conducted at the new JRR-4 reactor with full medical equipment installed. So far, there have been 9 patients treated and the phase I/II finished. The median survival of Glioblastoma cases is 15.4 months and 16months for anaplastic astrocytomas. This result is favorable for phase I/II study and merits for further new protocol using pure epithermal beam.
|
-
-
-
-
-
-
-
-
-
-
-
-
[Publications] Matsumura A, Shibata Y, Yamamoto T, Yoshida F, Isobe T, Nakai K, Hayakawa Y, Kiriya M, Shimojo N, Ono K, Sakata I, Nakajima S, Okumura M, Nose T.: "A new boronated porphyrin (STA-BX909) for neutron capture therapy : An in vitro survival assay and in vivo tissue uptake study (Published Erratum, Cancer Letters, 2000; 155: 209.)"Cancer Lett.. 141. 203-209 (1999)
Description
「研究成果報告書概要(欧文)」より
-
[Publications] Matsumaura A, Yamamoto T, Shibata Y, Zhang T, Takano S, Yamamoto K, Kumada H, Nose T et al., Sauerwein W, Moss R, Witting A eds.: "Intraoperative boron neutron capture therapy using thermal/epithermal mixed beam, Research and Development in Neutron Capture Therapy"Monduzzi Editore, Bologna. 1073-1078 (2002)
Description
「研究成果報告書概要(欧文)」より
-
-
-
-
